Anest. intenziv. Med. 2025;36(2):84-90 | DOI: 10.36290/aim.2025.015

Therapeutic drug monitoring - a path to more effective antibiotic therapyReview Article

Juhás V.1, 4, Šudáková A.2, 4, Harazim M.3, 4
1 Úsek klinické farmacie, Nemocniční lékárna Fakultní nemocnice Brno
2 Oddělení klinické biochemie Fakultní nemocnice Brno
3 Interní gastroenterologická klinika Fakultní nemocnice Brno
4 Lékařská fakulta Masarykovy univerzity Brno

Therapeutic drug monitoring (TDM) is a key tool in optimizing antibiotic therapy in critically ill patients. The variability of pharmacokinetics and pharmacodynamics (PK/PD) in this population often requires an individualized approach that goes beyond standard dosing schedules. Early implementation of TDM, especially during the first 48 hours of treatment, is essential to achieve target therapeutic antibiotic concentrations. The correct administration strategy, using prolonged or continuous infusions of the administered antibiotics, plays a significant role in achieving optimal PK/PD parameters. At our institution, we have observed a high variability in the concentrations achieved for β-lactam antibiotics over the years, which supports the wider implementation of TDM in routine clinical practice.

Keywords: therapeutic drug monitoring (TDM), antibiotic therapy, piperacillin/tazobactam, meropenem, cefepime, linezolid.

Received: February 10, 2025; Revised: April 7, 2025; Accepted: April 10, 2025; Published: June 27, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Juhás V, Šudáková A, Harazim M. Therapeutic drug monitoring - a path to more effective antibiotic therapy. Anest. intenziv. Med. 2025;36(2):84-90. doi: 10.36290/aim.2025.015.
Download citation
PDF will be unlocked 27.6.2026

References

  1. . Kollef MH, Shorr AF, Bassetti M, Timsit JF, Micek ST, Michelson AP, et al. Timing of antibiotic therapy in the ICU. Crit Care. 2021 Oct 15;25(1):360. doi: 10.1186/s13054-021-03787-z. PMID: 34654462; PMCID: PMC8518273. Go to original source... Go to PubMed...
  2. . Al­‑Shaer MH, Rubido E, Cherabuddi K, Venugopalan V, Klinker K, Peloquin C. Early therapeutic monitoring of β­‑lactams and associated therapy outcomes in critically ill patients. J Antimicrob Chemother. 2020 Dec 1;75(12):3644-3651. doi: 10.1093/jac/dkaa359. PMID: 32910809. Go to original source... Go to PubMed...
  3. . Pai Mangalore R, Ashok A, Lee SJ, Romero L, Peel TN, Udy AA, et al. Beta­‑Lactam Antibiotic Therapeutic Drug Monitoring in Critically Ill Patients: A Systematic Review and Meta­‑Analysis. Clin Infect, DiS. 2022 Nov 14;75(10):1848-1860. doi: 10.1093/cid/ciac506. PMID: 35731853; PMCID: PMC9662173. Go to original source... Go to PubMed...
  4. . Sadilova K, Halacova M, Cerny D. Pharmacokinetic Aspects Of Beta­‑Lactam Antibiotic Therapy In Intensive Care Unit Patients: A One­‑Center Experience With Tdm. Ceska A Slovenska Farmacie: Casopis Ceske Farmaceuticke Spolecnosti A Slovenske Farmaceuticke Spolecnosti. 2020; 69:17-23. Go to original source...
  5. . Claus BO, Hoste EA, Colpaert K, Robays H, Decruyenaere J, De Waele JJ. Augmented renal clearance is a common finding with worse clinical outcome in critically ill patients receiving antimicrobial therapy. J Crit Care. 2013 Oct;28(5):695-700. doi: 10.1016/j.jcrc.2013.03.003. Epub 2013 May 14. PMID: 23683557. Go to original source... Go to PubMed...
  6. . Roberts JA, De Waele JJ, Dimopoulos G, Koulenti D, Martin C, Montravers P, et al. DALI: Defining Antibiotic Levels in Intensive care unit patients: a multi­‑centre point of prevalence study to determine whether contemporary antibiotic dosing for critically ill patients is therapeutic. BMC Infect, DiS. 2012 Jul 6;12:152. doi: 10.1186/1471-2334-12-152. PMID: 22768873; PMCID: PMC3506523. Go to original source... Go to PubMed...
  7. . Guilhaumou R, Benaboud S, Bennis Y, Dahyot­‑Fizelier C, Dailly E, Gandia P, et al. Optimization of the treatment with beta­‑lactam antibiotics in critically ill patients­‑guidelines from the French Society of Pharmacology and Therapeutics (Société Française de Pharmacologie et Thérapeutique­‑SFPT) and the French Society of Anaesthesia and Intensive Care Medicine (Société Française d'Anesthésie et Réanimation­‑SFAR). Crit Care. 2019 Mar 29;23(1):104. doi: 10.1186/s13054-019-2378-9. PMID: 30925922; PMCID: PMC6441232. Go to original source... Go to PubMed...
  8. . Gaur P, Hada V, Rath RS, Mohanty A, Singh P, Rukadikar A. Interpretation of Antimicrobial Susceptibility Testing Using European Committee on Antimicrobial Susceptibility Testing (EUCAST) and Clinical and Laboratory Standards Institute (CLSI) Breakpoints: Analysis of Agreement. Cureus. 2023 Mar 31;15(3):e36977. doi: 10.7759/cureus.36977. PMID: 37139290; PMCID: PMC10149341. Go to original source... Go to PubMed...
  9. . Tran NN, Mynatt RP, Kaye KS, Zhao JJ, Pogue JM. Clinical Outcomes With Extended Versus Intermittent Infusion of Anti­‑Pseudomonal Beta­‑Lactams in Patients With Gram­‑Negative Bacteremia. Open Forum Infect, DiS. 2023 Mar 27;10(4):ofad170. doi: 10.1093/ofid/ofad170. Erratum in: Open Forum Infect, DiS. 2023 Jun 13;10(6):ofad309. doi: 10.1093/ofid/ofad309. PMID: 37125229; PMCID: PMC10135424. Go to original source... Go to PubMed...
  10. . Abdul­‑Aziz MH, Lipman J, Akova M, Bassetti M, De Waele JJ, Dimopoulos G, et al; DALI Study Group. Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patients (DALI) cohort. J Antimicrob Chemother. 2016 Jan;71(1):196-207. doi: 10.1093/jac/dkv288. Epub 2015 Oct 3. PMID: 26433783. Go to original source... Go to PubMed...
  11. . Roberts JA, Paul SK, Akova M, Bassetti M, De Waele JJ, Dimopoulos G, et al; DALI Study. DALI: defining antibiotic levels in intensive care unit patients: are current β­‑lactam antibiotic doses sufficient for critically ill patients? Clin Infect, DiS. 2014 Apr;58(8):1072-83. doi: 10.1093/cid/ciu027. Epub 2014 Jan 14. PMID: 24429437. Go to original source... Go to PubMed...
  12. . Dulhunty JM, Brett SJ, De Waele JJ, Rajbhandari D, Billot L, Cotta MO, et al; BLING III Study Investigators. Continuous vs Intermittent β­‑Lactam Antibiotic Infusions in Critically Ill Patients With Sepsis: The BLING III Randomized Clinical Trial. JAMA. 2024 Aug 27;332(8):629-637. doi: 10.1001/jama.2024.9779. PMID: 38864155; PMCID: PMC11170452. Go to original source... Go to PubMed...
  13. . Karaba SM, Cosgrove SE, Lee JH, Fiawoo S, Heil EL, Quartuccio KS, et al. Extended­‑Infusion β­‑Lactam Therapy, Mortality, and Subsequent Antibiotic Resistance Among Hospitalized Adults With Gram­‑Negative Bloodstream Infections. JAMA Netw Open. 2024 Jul 1;7(7):e2418234. doi: 10.1001/jamanetworkopen.2024.18234. PMID: 38954416; PMCID: PMC11220563. Go to original source... Go to PubMed...
  14. . Lexidrug U. Multinational/Drugs 2025. Verze 8. 4. 2 (862) [cited 7. 2. 2025].
  15. . Schoenenberger­‑Arnaiz JA, Ahmad­‑Diaz F, Miralbes­‑Torner M, Aragones­‑Eroles A, Cano­‑Marron M, Palomar­‑Martinez M. Usefulness of therapeutic drug monitoring of piperacillin and meropenem in routine clinical practice: a prospective cohort study in critically ill patients. Eur J Hosp Pharm. 2020 Mar;27(e1):e30-e35. doi: 10.1136/ejhpharm-2018-001713. Epub 2019 Feb 27. PMID: 32296502; PMCID: PMC7147564. Go to original source... Go to PubMed...
  16. . Scharf C, Paal M, Schroeder I, Vogeser M, Draenert R, Irlbeck M, Zoller M, Liebchen U. Therapeutic Drug Monitoring Of Meropenem And Piperacillin In Critical Illness­‑Experience And Recommendations From One Year In Routine Clinical Practice. Antibiotics­‑Basel. 2020; 9. 10. 3390/Antibiotics9030131. Go to original source... Go to PubMed...
  17. . Imani S, Buscher H, Marriott D, Gentili S, Sandaradura I. Too much of a good thing: a retrospective study of β­‑lactam concentration­‑toxicity relationships. J Antimicrob Chemother. 2017 Oct 1;72(10):2891-2897. doi: 10.1093/jac/dkx209. PMID: 29091190. Go to original source... Go to PubMed...
  18. . Quinton M, Bodeau S, Kontar L, Zerbib Y, Maizel J, Slama M, et al. Neurotoxic Concentration Of Piperacillin During Continuous Infusion In Critically Ill 356 Patients. Antimicrob Agents Chemother. 2017;61:e00654-17. Go to original source... Go to PubMed...
  19. . Thalhammer F, Hörl W. Pharmacokinetics of meropenem in patients with renal failure and patients receiving renal replacement therapy. Clin Pharmacokinet. 2000;39:271-279.20 Go to original source... Go to PubMed...
  20. . Hong L, Downes K, Fakhriravari A, Abdul-Mutakabbir J, Kuti J, Jorgensen S, et al. International consensus recommendations for the use of prolonged-infusion beta-lactam antibiotics: endorsed by the American College of Clinical Pharmacy, British Society for Antimicrobial Chemotherapy, Cystic Fibrosis Foundation, European Society of Clinical Microbiology and Infectious Diseases, Infectious Diseases Society of America, Society of Critical Care Medicine, and Society of Infectious Diseases Pharmacists: an executive summary. Pharmacotherapy. 2023;43:736-739 Go to original source... Go to PubMed...
  21. . Wong G, Briscoe S, McWhinney B, Ally M, Ungerer J, Lipman J, et al. Therapeutic drug monitoring of β­‑lactam antibiotics in the critically ill: direct measurement of unbound drug concentrations to achieve appropriate drug exposures. J Antimicrob Chemother. 2018 Nov 1;73(11):3087-3094. doi: 10.1093/jac/dky314. PMID: 30137377. Go to original source... Go to PubMed...
  22. . Roger C, Louart B. Beta­‑Lactams Toxicity in the Intensive Care Unit: An Underestimated Collateral Damage? Microorganisms. 2021 Jul 14;9(7):1505. doi: 10.3390/microorganisms9071505. PMID: 34361942; PMCID: PMC8306322. Go to original source... Go to PubMed...
  23. . Khole AV, Dionne E, Zitek­‑Morrison E, Campion M. Cefepime extended infusion versus intermittent infusion: Clinical and cost evaluation. Antimicrob Steward Healthc Epidemiol. 2023 Jul 10;3(1):e119. doi: 10.1017/ash.2023.179. PMID: 37502254; PMCID: PMC10369431. Go to original source... Go to PubMed...
  24. . Payne LE, Gagnon DJ, Riker RR, Seder DB, Glisic EK, Morris JG, et al. Cefepime­‑induced neurotoxicity: a systematic review. Crit Care. 2017 Nov 14;21(1):276. doi: 10.1186/s13054-017-1856-1. PMID: 29137682; PMCID: PMC5686900. Go to original source... Go to PubMed...
  25. . Venugopalan V, Casaus D, Kainz L, Slaton CN, Hurst N, Bruzzone M, et al. Use of therapeutic drug monitoring to characterize cefepime­‑related neurotoxicity. Pharmacotherapy. 2023 Jan;43(1):6-14. doi: 10.1002/phar.2744. Epub 2022 Dec 2. PMID: 36401796. Go to original source... Go to PubMed...
  26. . Lodl EF, Alshaer MH, Adams CB, Richards A, Peloquin C, Venugopalan V. Utilization of cefepime therapeutic drug monitoring in febrile neutropenia patients with hematologic malignancies. J Oncol Pharm Pract. 2024 Oct;30(7):1207-1213. doi: 10.1177/10781552231213883. Epub 2023 Nov 19. PMID: 37981806. Go to original source... Go to PubMed...
  27. . Rao GG, Konicki R, Cattaneo D, Alffenaar JW, Marriott DJE, Neely M; IATDMCT Antimicrobial Scientific Committee. Therapeutic Drug Monitoring Can Improve Linezolid Dosing Regimens in Current Clinical Practice: A Review of Linezolid Pharmacokinetics and Pharmacodynamics. Ther Drug Monit. 2020 Feb;42(1):83-92. doi: 10.1097/FTD.0000000000000710. PMID: 31652190. Go to original source... Go to PubMed...
  28. . Thirot H, Fage D, Leonhardt A, Clevenbergh P, Besse­‑Hammer T, Yombi J, et al. Towards A Better Detection Of Patients At­‑Risk Of Linezolid Toxicity In Clinical Practice: A Prospective Study In Three Belgian Hospital Centers. Frontiers In Pharmacology. 2024; 15. 10. 3389/Fphar.2024.1310309. Go to original source... Go to PubMed...
  29. . Inoue Y, Kashiwagi H, Sato Y, Nashimoto S, Sugawara M, Takekuma Y. Exploring the impact of baseline platelet count on linezolid­‑induced thrombocytopenia: a retrospective single­‑center observation study. Int J Clin Pharm. 2025 Feb;47(1):90-98. doi: 10.1007/s11096-024-01810-1. Epub 2024 Oct 4. PMID: 39365521. Go to original source... Go to PubMed...
  30. . Lin B, Hu Y, Xu P, Xu T, Chen C, He L, et al. Expert consensus statement on therapeutic drug monitoring and individualization of linezolid. Front Public Health. 2022 Aug 10;10:967311. doi: 10.3389/fpubh.2022.967311. PMID: 36033811; PMCID: PMC9399604. Go to original source... Go to PubMed...
  31. . Lau C, Marriott D, Bui J, Figtree M, Gould M, Chubaty A, et al. LInezolid Monitoring to MInimise Toxicity (LIMMIT1): A multicentre retrospective review of patients receiving linezolid therapy and the impact of therapeutic drug monitoring. Int J Antimicrob Agents. 2023 May;61(5):106783. doi: 10.1016/j.ijantimicag.2023.106783. Epub 2023 Mar 14. PMID: 36921808. Go to original source... Go to PubMed...
  32. . Xu Y, Yang X, Liang P, Qu C. Linezolid dose adjustment according to therapeutic drug monitoring helps reach the goal concentration in severe patients, and the oldest seniors benefit more. BMC Infect, DiS. 2023 Nov 29;23(1):840. doi: 10.1186/s12879-023-08831-7. PMID: 38030977; PMCID: PMC10685494. Go to original source... Go to PubMed...
  33. . Ferrari F, Sartori M, Milla P, Ronco C, Bellomo R, Kellum J, et al. Chapter 175 - Antibiotic Adjustment In Continuous Renal Replacement Therapy. Critical Care Nephrology (Third Edition). Philadelphia: Elsevier; 2019. Go to original source...
  34. . Grupper M, Kuti JL, Nicolau DP. Continuous and Prolonged Intravenous β­‑Lactam Dosing: Implications for the Clinical Laboratory. Clin Microbiol Rev. 2016 Oct;29(4):759-72. doi: 10.1128/CMR.00022-16. PMID: 27413094; PMCID: PMC5010748. Go to original source... Go to PubMed...
  35. . Chromsystems Rg. Instruction Manual For Hplc Determination: Antibiotics In Serum/Plasma. 2024. R1. 2. Gräfelfing: Chromsystems. 2024. Available from: Https://Chromsystems.Com/En/Antibiotics­‑In­‑Serum­‑Plasma­‑Hplc-61000.html.




Anesteziologie a intenzivní medicína

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.